XOSL
CONTX
Market cap25mUSD
Jul 22, Last price
3.27NOK
1D
-3.82%
1Q
-9.67%
Jan 2017
-33.94%
Name
ContextVision AB
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
ContextVision AB (publ), a medical technology enterprise established in Stockholm, Sweden, in 1983, delivers sophisticated software solutions. The firm specializes in image analysis and artificial intelligence, supplying these advanced technologies to original equipment manufacturers (OEMs) across Asia, Europe, and the United States. Their comprehensive product suite is designed to optimize image quality across various medical imaging modalities, including two-dimensional, three-dimensional, and four-dimensional ultrasound, radiography, magnetic resonance imaging (MRI), and mammography. Key offerings include: Rivent: Provides superior image quality for a broad spectrum of ultrasound applications such as women's health, general imaging, cardiovascular, and point-of-care. VolarView: An image enhancement software specifically developed for the burgeoning handheld ultrasound market. GOPiCE: A proprietary technology enabling real-time volumetric image enhancement. Altumira/Altumira Plus: A robust platform for digital radiography. An Orthopedic Package: Tailored for specialized orthopedic imaging needs. GOPView MRI2Plus: An advanced solution for MRI image improvement. INIFY Prostate Screening: Offers digital analysis for prostate biopsies.
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||